These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 8021689)

  • 21. Is there a genetic susceptibility locus for Parkinson's disease on chromosome 22q13?
    Wilhelmsen K; Mirel D; Marder K; Bernstein M; Naini A; Leal SM; Cote LJ; Tang MX; Freyer G; Graziano J; Mayeux R
    Ann Neurol; 1997 Jun; 41(6):813-7. PubMed ID: 9189044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of debrisoquine hydroxylation phenotypes.
    Wolf CR; Moss JE; Miles JS; Gough AC; Spurr NK
    Lancet; 1990 Dec; 336(8728):1452-3. PubMed ID: 1978915
    [No Abstract]   [Full Text] [Related]  

  • 23. Debrisoquine 4-hydroxylase (CYP2D) locus and possible susceptibility to schizophrenia.
    Vallada H; Collier D; Dawson E; Owen M; Nanko S; Murray R; Gill M
    Lancet; 1992 Jul; 340(8812):181-2. PubMed ID: 1352597
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmacogenetics: Part II.
    Gibaldi M
    Ann Pharmacother; 1992 Feb; 26(2):255-61. PubMed ID: 1554942
    [No Abstract]   [Full Text] [Related]  

  • 25. P450 enzymes and Parkinson's disease: the story so far.
    Riedl AG; Watts PM; Jenner P; Marsden CD
    Mov Disord; 1998 Mar; 13(2):212-20. PubMed ID: 9539332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [CYP2D6 genotype determination].
    Brøsen K
    Ugeskr Laeger; 1993 Nov; 155(46):3779-80. PubMed ID: 8256376
    [No Abstract]   [Full Text] [Related]  

  • 27. R296C and other CYP2D6 mutations in Chinese.
    Wang SL; Lai MD; Lai ML; Huang JD
    Pharmacogenetics; 1995 Dec; 5(6):385-8. PubMed ID: 8747410
    [No Abstract]   [Full Text] [Related]  

  • 28. Lewy bodies, Alzheimer pathology and APP mutation.
    Masliah E; Saitoh T
    Neurosci Lett; 1994 Oct; 180(2):292-3. PubMed ID: 7700597
    [No Abstract]   [Full Text] [Related]  

  • 29. Concordance of phenotype and genotype for CYP2D6.
    McLeod HL
    Clin Pharmacol Ther; 1994 Oct; 56(4):463-4. PubMed ID: 7955809
    [No Abstract]   [Full Text] [Related]  

  • 30. NcoI RFLP in the pseudogene (CYP2D8P) of the human debrisoquine 4-hydroxylase locus.
    Mura C; Broyart JP; Jacqz E; Elion J; Krishnamoorthy R
    Nucleic Acids Res; 1991 Mar; 19(5):1162. PubMed ID: 1673559
    [No Abstract]   [Full Text] [Related]  

  • 31. Polymorphism of human CYP2D genes involved in drug metabolism: possible relationship to individual cancer risk.
    Nebert DW
    Cancer Cells; 1991 Mar; 3(3):93-6. PubMed ID: 2054261
    [No Abstract]   [Full Text] [Related]  

  • 32. Debrisoquine hydroxylase gene polymorphism in Parkinson's disease and amyotrophic lateral sclerosis.
    Ray-Chaudhuri K; Smith C; Gough AC; Novak N; Chamoun V; Wolf CR; Leigh PN
    J Neurol Neurosurg Psychiatry; 1995 Jan; 58(1):109. PubMed ID: 7823053
    [No Abstract]   [Full Text] [Related]  

  • 33. Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease.
    Kurth MC; Kurth JH
    Am J Med Genet; 1993 Oct; 48(3):166-8. PubMed ID: 8291573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CYP2D6 genotyping and the association with lung cancer susceptibility.
    Wolf CR; Smith CA; Bishop T; Forman D; Gough AC; Spurr NK
    Pharmacogenetics; 1994 Apr; 4(2):104-6. PubMed ID: 8081411
    [No Abstract]   [Full Text] [Related]  

  • 35. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
    Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
    Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Localization of the CYP2D gene locus to human chromosome 22q13.1 by polymerase chain reaction, in situ hybridization, and linkage analysis.
    Gough AC; Smith CA; Howell SM; Wolf CR; Bryant SP; Spurr NK
    Genomics; 1993 Feb; 15(2):430-2. PubMed ID: 8449513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism.
    Mikus G; Bochner F; Eichelbaum M; Horak P; Somogyi AA; Spector S
    J Pharmacol Exp Ther; 1994 Feb; 268(2):546-51. PubMed ID: 8113966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Genetic polymorphisms of drug metabolizing enzymes].
    Fujieda M; Yamazaki H; Kamataki T
    Gan To Kagaku Ryoho; 2002 May; 29(5):663-8. PubMed ID: 12040668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
    Broly F; Meyer UA
    Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mitochondrial NADH dehydrogenase and CYP2D6 genotypes in Lewy-body parkinsonism.
    Kösel S; Lücking CB; Egensperger R; Mehraein P; Graeber MB
    J Neurosci Res; 1996 Apr; 44(2):174-83. PubMed ID: 8723226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.